NATIONAL HARBOR, Md. — A novel immunomodulatory therapy demonstrated antitumor activity across a broad range of heavily pretreated, immunotherapy-resistant tumors, including objective responses in advanced non-small cell lung cancer (NSCLC), a preliminary study showed.
Treatment with the Siglec-15-targeted monoclonal antibody NC318 led to disease control (response and stable disease) in one-third of the 49 patients on study. The activity included one complete response, one partial response, and four cases of prolonged disease stabilization in the 13 patients with advanced NSCLC.